Abstract 250P
Background
Adjuvant treatment for patients (pts) with endometrial cancer (EC) is decided based on risk assessment of recurrence and distant metastasis. Carcinomas of non-endometrioid (NE) histologies are rare, classified as high-risk and adjuvant treatment is recommended.
Methods
Retrospective analysis of EC pts diagnosed and treated in two units during 10 years (2009-2018) with a focus on pts with NEEC. After surgery and multidisciplinary discussion, pts had either no further treatment, radiotherapy (RT), chemotherapy (CT) followed by RT or CT. We compared these approaches using survival analysis.
Results
From a total of 330 pts with EC, 66 pts with surgery for NEEC were analyzed. Median age was 68.5 yrs (43-88). Serous histology was found in 34 (51.5%) pts, clear-cell in 13 (19.7%), in 18 (27.3%) carcinosarcoma and one pt had an undifferentiated tumor. Based on the International Federation of Gynecology and Obstetrics (FIGO) staging system, 32 pts (48.5%) were diagnosed at early stage (IA-II) and 34 (51,5%) at advanced stage (IIIA-IV). After surgery, 16 pts (24.4%) had no further treatment, while 11 (16.7%) received CT, 28 (42.4%) CT + RT and 11 (16.7%) only RT. RT included external beam RT and/or brachytherapy. In the survival analysis, the median DFS was significantly higher in the CT + RT group, 31 months (m), compared to both the RT alone group, 14m and the isolated CT group, 11m. For patients without further treatment DFS was 6m, p = 0.03. The median OS showed similar results: pts submitted to CT + RT had favorable survival (78m) compared to the other groups, RT group (64m), CT group (37m) and the group of pts with no further treatment (47m), p = 0.005.
Conclusions
The best survival results are for pts treated with CT+RT. Patients treated with RT had better results when compared with pts treated with CT or with pts without further treatment. These results show us that pts treated with CT are those with higher FIGO stages that were not considered for adjuvant RT. The worse survival results for untreated pts reflects deteriorated PS, extensive comorbidities or early progression. Due to aging and lifestyle risk factors, like obesity, EC remains the most prevalent gynecological carcinoma where better selection and implementation of adjuvant treatment modalities are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Author and co-authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract